Publications

452 publications

Enter search criteria
Fill in keyword(s) to narrow your search.
Period
You can select a specific type of a publication you are looking for, such as press releases or speeches
Sort by:
  1. Advice on the clustering of combination products and ghost clusters in GVS (part 4)

    The Minister of Medical Care has asked the National Health Care Institute questions about the clustering of two categories of ...

    Report | 23-05-2023

  2. Advice on the clustering of combination products and ghost clusters in GVS (part 3)

    The Minister of Medical Care has asked the National Health Care Institute questions about the clustering of two categories of ...

    Report | 23-05-2023

  3. GVS advice dapagliflozin (Forxiga®) extension of List 2 conditions

    The National Health Care Institute has assessed whether the reimbursement conditions for dapagliflozin (Forxiga®) can be ...

    Report | 23-05-2023

  4. Advice on the clustering of combination products and ghost clusters in GVS (part 2)

    The Minister of Medical Care has asked the National Health Care Institute questions about the clustering of two categories of ...

    Report | 23-05-2023

  5. Package advice lenvatinib (Kisplix®) in combination with pembrolizumab for the treatment of renal cell carcinoma

    The National Health Care Institute has assessed whether the medicinal product lenvatinib (Kisplix®) in combination with ...

    Report | 15-05-2023

  6. GVS advice on the re-assessment of vericiguat (Verquvo®) for the treatment of adults with chronic heart failure

    The National Health Care Institute has assessed whether the medicinal product vericiguat (Verquvo®) can be included in the ...

    Report | 12-05-2023

  7. Package advice vitamin D

    The National Health Care Institute recommends that all colecalciferol-containing medicinal products and calcifediol be removed ...

    Report | 09-05-2023

  8. Advisory report on possible candidate for conditional inclusion of atidarsagene autotemcel (Libmeldy®)

    The National Health Care Institute advises the Minister of Health, Welfare and Sport (VWS) to designate atidarsagene autotemcel ...

    Report | 08-05-2023

  9. Evaluation of orphan drugs arrangement eculizumab (Soliris®) for the treatment of atypical Haemolytic Uraemic Syndrome (aHUS)

    The National Health Care Institute concludes that agreements made in 2016 about the use of the medicinal product eculizumab ...

    Letter | 08-05-2023

  10. GVS advice on lanadelumab (Takhzyro®) for the prevention of recurrent attacks of hereditary angioedema (HAE)

    The National Health Care Institute has assessed whether the medicinal product lanadelumab (Takhzyro®) can be included in the ...

    Report | 28-04-2023